ADC Therapeutics SA
About ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $81.4M
- Net income
- -$142.6M
- Total assets
- $323.1M
- Market cap
- $131.0M
- Gross margin
- 92.9%
- Operating margin
- -149.3%
- Net margin
- -175.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $81.4M
- Cost of revenue
- $5.8M
- Gross profit
- $75.6M
- Operating expenses
- $197.1M
- Operating income
- -$121.5M
- Income tax
- $1.0M
- Net income
- -$142.6M
- EPS (basic)
- $-1.12
- EPS (diluted)
- $-1.12
Balance sheet
- Total assets
- $323.1M
- Current assets
- $306.3M
- Total liabilities
- $509.0M
- Current liabilities
- $70.2M
- Shareholders’ equity
- -$185.8M
Cash flow
- Operating cash flow
- -$141.2M
- Investing cash flow
- $395.0K
- Financing cash flow
- $150.9M
- Net cash flow
- $10.5M
Statements via Polygon.io (SEC filings)
- Market cap
- $131.0M
- EPS (diluted)
- $-1.12
- Shares outstanding
- 133.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $142.6M in FY2025.
- Revenue grew 17% from FY2023 to FY2025.
- Gross margin of 92.9%, net margin -175.3%.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ADC Therapeutics SA.
Write a review
News about ADC Therapeutics SA
News & sentiment via Polygon.io
